Agata A Exner Selected Research

Poloxamer (Poloxamer 407)

1/2019	Time-intensity-curve Analysis and Tumor Extravasation of Nanobubble Ultrasound Contrast Agents.
6/2014	Nanobubble ultrasound contrast agents for enhanced delivery of thermal sensitizer to tumors undergoing radiofrequency ablation.
10/2013	Preclinical evaluation of radiosensitizing activity of Pluronic block copolymers.
1/2011	Structural parameters governing activity of Pluronic triblock copolymers in hyperthermia cancer therapy.
1/2011	Role of Pluronic block copolymers in modulation of heat shock protein 70 expression.
1/2009	Time and dose dependence of pluronic bioactivity in hyperthermia-induced tumor cell death.
3/2008	Combination of sensitizing pretreatment and radiofrequency tumor ablation: evaluation in rat model.
7/2007	Effect of intratumoral injection of carboplatin combined with pluronic P85 or L61 on experimental colorectal carcinoma in rats.
8/2005	Enhancement of carboplatin toxicity by Pluronic block copolymers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Agata A Exner Research Topics

Disease

49	Neoplasms (Cancer) 01/2023 - 08/2005
7	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 08/2005
6	Hyperthermia 06/2014 - 03/2008
3	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2020
3	Hepatocellular Carcinoma (Hepatoma) 03/2020 - 01/2016
3	Residual Neoplasm 03/2012 - 03/2008
3	Adenocarcinoma 01/2011 - 07/2007
3	Carcinoma (Carcinomatosis) 03/2008 - 12/2006
2	Breast Neoplasms (Breast Cancer) 12/2019 - 01/2019
2	Ovarian Neoplasms (Ovarian Cancer) 01/2019 - 10/2017
2	Necrosis 07/2017 - 01/2014
2	Liver Neoplasms (Liver Cancer) 10/2008 - 04/2007
1	Hepatitis 03/2020
1	Infections 03/2020
1	Disease Progression 01/2020
1	Neoplasm Metastasis (Metastasis) 12/2019
1	Melanoma (Melanoma, Malignant) 12/2019
1	Cysts 12/2018
1	Ovarian Epithelial Carcinoma 10/2017
1	Glioma (Gliomas) 10/2013
1	Colonic Neoplasms (Colon Cancer) 03/2012
1	Inflammation (Inflammations) 04/2007

Drug/Important Bio-Agent (IBA)

19	Pharmaceutical PreparationsIBA 01/2023 - 08/2005
16	Contrast MediaIBA 01/2023 - 07/2013
9	Poloxamer (Poloxamer 407)IBA 01/2019 - 08/2005
5	PolymersIBA 10/2008 - 12/2005
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2015
4	AntigensIBA 01/2022 - 10/2017
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016 - 04/2007
3	Adenosine Triphosphate (ATP)IBA 01/2020 - 01/2011
3	LipidsIBA 01/2019 - 06/2014
3	pluronic L61IBA 01/2011 - 07/2007
3	Carboplatin (JM8)FDA LinkGeneric 07/2007 - 08/2005
2	IntegrinsIBA 01/2021 - 01/2018
2	perflutren (octafluoropropane)FDA Link 01/2019 - 11/2013
2	Surface-Active Agents (Surfactants)IBA 10/2017 - 10/2013
2	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 06/2014 - 01/2011
2	UCON 50-HB-5100 (F127)IBA 01/2011 - 08/2005
2	Hydralazine (Apresoline)FDA LinkGeneric 03/2009 - 03/2009
2	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 03/2009 - 03/2009
1	pyrrolidin-3-yl-methanesulfonic acid (PMSA)IBA 01/2022
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2022
1	Tumor Biomarkers (Tumor Markers)IBA 01/2022
1	Class 2 Receptor-Like Protein Tyrosine PhosphatasesIBA 02/2021
1	gluconic acid (gluconate)FDA LinkGeneric 01/2021
1	aspartic acid glycine arginineIBA 01/2021
1	N(delta)- (N- methyl- N- nitrosocarbamoyl)- L- ornithine (MNCO)IBA 01/2021
1	Protons (Proton)IBA 03/2020
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2020
1	hexamethylene bisacetamide (HMBA)IBA 12/2019
1	acetamideIBA 12/2019
1	histone H3 trimethyl Lys4IBA 12/2019
1	Proteins (Proteins, Gene)FDA Link 12/2019
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 12/2019
1	Histone DemethylasesIBA 12/2019
1	Phenobarbital (Luminal)FDA Link 12/2018
1	PorphyrinsIBA 01/2018
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2018
1	Polyvinyl AlcoholIBA 07/2017
1	Bumetanide (Bumex)FDA LinkGeneric 07/2017
1	DNA (Deoxyribonucleic Acid)IBA 10/2013
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 10/2013
1	Ethylene Oxide (Oxirane)IBA 01/2011
1	propylene oxideIBA 01/2011
1	Polylactic Acid-Polyglycolic Acid CopolymerIBA 11/2010
1	Hematoxylin (Haematoxylon)IBA 12/2009
1	Monoclonal AntibodiesIBA 12/2009
1	Eosine Yellowish-(YS) (Eosin)IBA 12/2009
1	Vasoconstrictor AgentsIBA 03/2009
1	Vasodilator Agents (Vasodilators)IBA 03/2009
1	Antineoplastic Agents (Antineoplastics)IBA 01/2009
1	ElementsIBA 12/2007
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 07/2007
1	Capsules (Microcapsules)IBA 04/2007
1	SuspensionsIBA 12/2006
1	Fluorouracil (Carac)FDA LinkGeneric 12/2005
1	5-fluorouridineIBA 12/2005

Therapy/Procedure

16	Therapeutics 01/2022 - 08/2005
10	Microbubbles 01/2022 - 02/2010
7	Drug Therapy (Chemotherapy) 12/2019 - 12/2006
7	Radiofrequency Ablation 06/2014 - 12/2005
4	Precision Medicine 01/2021 - 06/2014
2	Injections 01/2015 - 12/2006
2	Adjuvant Chemotherapy 08/2010 - 12/2006
1	Castration 01/2022
1	Photochemotherapy (Photodynamic Therapy) 01/2022
1	Laparotomy 01/2022
1	Subcutaneous Injections 11/2010
1	Induced Hyperthermia (Thermotherapy) 01/2009
1	Intravenous Injections 03/2008
1	Absorbable Implants 12/2007
1	Aftercare (After-Treatment) 04/2007